candesartan cilexetil has been researched along with Cirrhosis in 10 studies
candesartan cilexetil: a prodrug which is metabolized to an active form candesartan to exert its biological effects
| Excerpt | Relevance | Reference |
|---|---|---|
| "Candesartan cilexetil treatment improved cardiac structural remodeling and cardiac function in SDT rats." | 5.35 | Long-term angiotensin II blockade may improve not only hyperglycemia but also age-associated cardiac fibrosis. ( Fukumoto, M; Hayashi, T; Ikeda, T; Jin, D; Kitaura, Y; Miyazaki, M; Oku, H; Sugiyama, T; Takai, S, 2009) |
| " To examine the long-term effects of Candesartan cilexetil, an angiotensin type 1 (AT1) receptor blocker, on portal-systemic haemodynamics and on liver fibrosis." | 5.12 | AT1 receptor antagonist Candesartan in selected cirrhotic patients: effect on portal pressure and liver fibrosis markers. ( Alessandria, C; Biasi, F; Bonardi, R; Brunello, F; Debernardi-Venon, W; Martini, S; Marzano, A; Poli, G; Rizzetto, M; Saracco, G; Termine, A; Vizio, B, 2007) |
| "Candesartan cilexetil treatment improved cardiac structural remodeling and cardiac function in SDT rats." | 1.35 | Long-term angiotensin II blockade may improve not only hyperglycemia but also age-associated cardiac fibrosis. ( Fukumoto, M; Hayashi, T; Ikeda, T; Jin, D; Kitaura, Y; Miyazaki, M; Oku, H; Sugiyama, T; Takai, S, 2009) |
| "We randomized db/db mice, a model of type 2 diabetes with obesity, at the age of 8 weeks to receive candesartan, an ARB, for 6 weeks." | 1.33 | Beneficial effects of candesartan, an angiotensin II type 1 receptor blocker, on beta-cell function and morphology in db/db mice. ( Hirose, T; Ikeda, F; Iwashita, N; Kawamori, R; Ogihara, T; Shao, J; Shimizu, T; Uchida, T; Uchino, H; Watada, H, 2006) |
| "A model of pacing-induced congestive heart failure (CHF) was used to test the central hypothesis that ARB + ACEI prevents myocardial fibrosis and decreases LV stiffness to a greater extent than ARB or ACEI alone." | 1.32 | Combined angiotensin receptor blocker and ACE inhibitor on myocardial fibrosis and left ventricular stiffness in dogs with heart failure. ( Dohi, K; Funabiki, K; Imanaka-Yoshida, K; Isaka, N; Ito, M; Koji, T; Nakano, T; Nobori, T; Onishi, K; Wada, H, 2004) |
| "In vehicle-treated rats, proteinuria, glomerulosclerosis, interstitial mononuclear cell (MNC) infiltration and interstitial fibrosis developed." | 1.30 | Effects of candesartan cilexetil (TCV-116) and enalapril in 5/6 nephrectomized rats. ( Fukuda, R; Imura, Y; Matsuo, T; Nagano, H; Nishikawa, K; Noda, M; Ohta, M; Shibouta, Y, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (20.00) | 18.2507 |
| 2000's | 7 (70.00) | 29.6817 |
| 2010's | 1 (10.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chow, BSM | 1 |
| Kocan, M | 1 |
| Shen, M | 1 |
| Wang, Y | 1 |
| Han, L | 1 |
| Chew, JY | 1 |
| Wang, C | 1 |
| Bosnyak, S | 1 |
| Mirabito-Colafella, KM | 1 |
| Barsha, G | 1 |
| Wigg, B | 1 |
| Johnstone, EKM | 1 |
| Hossain, MA | 1 |
| Pfleger, KDG | 1 |
| Denton, KM | 1 |
| Widdop, RE | 2 |
| Summers, RJ | 1 |
| Bathgate, RAD | 1 |
| Hewitson, TD | 1 |
| Samuel, CS | 1 |
| Jin, D | 1 |
| Takai, S | 1 |
| Sugiyama, T | 1 |
| Hayashi, T | 1 |
| Fukumoto, M | 1 |
| Oku, H | 1 |
| Kitaura, Y | 1 |
| Ikeda, T | 1 |
| Miyazaki, M | 1 |
| Jones, ES | 1 |
| Black, MJ | 1 |
| Funabiki, K | 1 |
| Onishi, K | 1 |
| Dohi, K | 1 |
| Koji, T | 1 |
| Imanaka-Yoshida, K | 1 |
| Ito, M | 1 |
| Wada, H | 1 |
| Isaka, N | 1 |
| Nobori, T | 1 |
| Nakano, T | 1 |
| Yamamoto, K | 2 |
| Mano, T | 2 |
| Yoshida, J | 2 |
| Sakata, Y | 2 |
| Nishikawa, N | 2 |
| Nishio, M | 1 |
| Ohtani, T | 1 |
| Hori, M | 3 |
| Miwa, T | 2 |
| Masuyama, T | 2 |
| Shao, J | 1 |
| Iwashita, N | 1 |
| Ikeda, F | 1 |
| Ogihara, T | 1 |
| Uchida, T | 1 |
| Shimizu, T | 1 |
| Uchino, H | 1 |
| Hirose, T | 1 |
| Kawamori, R | 1 |
| Watada, H | 1 |
| Debernardi-Venon, W | 1 |
| Martini, S | 1 |
| Biasi, F | 1 |
| Vizio, B | 1 |
| Termine, A | 1 |
| Poli, G | 1 |
| Brunello, F | 1 |
| Alessandria, C | 1 |
| Bonardi, R | 1 |
| Saracco, G | 1 |
| Rizzetto, M | 1 |
| Marzano, A | 1 |
| Noda, M | 1 |
| Fukuda, R | 1 |
| Matsuo, T | 1 |
| Ohta, M | 1 |
| Nagano, H | 1 |
| Imura, Y | 1 |
| Nishikawa, K | 1 |
| Shibouta, Y | 1 |
| Moriyama, T | 1 |
| Kawada, N | 1 |
| Akagi, Y | 1 |
| Ando, A | 1 |
| Horio, M | 1 |
| Yamauchi, A | 1 |
| Nagata, K | 1 |
| Imai, E | 1 |
| Sugawara, M | 1 |
| Yamaguchi, Y | 1 |
| Ookawara, T | 1 |
| Suzuki, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Beneficial Effect of Angiotensin-blocking Agent Candesartan on Alcoholic Liver Fibrosis: A Randomized Controlled Trial[NCT00990639] | Phase 1/Phase 2 | 85 participants (Actual) | Interventional | 2005-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for candesartan cilexetil and Cirrhosis
| Article | Year |
|---|---|
AT1 receptor antagonist Candesartan in selected cirrhotic patients: effect on portal pressure and liver fibrosis markers.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Female; Fibrosis | 2007 |
9 other studies available for candesartan cilexetil and Cirrhosis
| Article | Year |
|---|---|
AT1R-AT2R-RXFP1 Functional Crosstalk in Myofibroblasts: Impact on the Therapeutic Targeting of Renal and Cardiac Fibrosis.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Cells, Culture | 2019 |
Long-term angiotensin II blockade may improve not only hyperglycemia but also age-associated cardiac fibrosis.
Topics: Aging; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; An | 2009 |
Angiotensin AT2 receptor contributes to cardiovascular remodelling of aged rats during chronic AT1 receptor blockade.
Topics: Aging; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Block | 2004 |
Combined angiotensin receptor blocker and ACE inhibitor on myocardial fibrosis and left ventricular stiffness in dogs with heart failure.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimid | 2004 |
ACE inhibitor and angiotensin II type 1 receptor blocker differently regulate ventricular fibrosis in hypertensive diastolic heart failure.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting En | 2005 |
Beneficial effects of candesartan, an angiotensin II type 1 receptor blocker, on beta-cell function and morphology in db/db mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Blood Glucose; | 2006 |
Effects of candesartan cilexetil (TCV-116) and enalapril in 5/6 nephrectomized rats.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; | 1997 |
TCV-116 inhibits interstitial fibrosis and HSP47 mRNA in rat obstructive nephropathy.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; | 1997 |
Myocardial stiffness is determined by ventricular fibrosis, but not by compensatory or excessive hypertrophy in hypertensive heart.
Topics: Analysis of Variance; Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; | 2002 |